Form D — Vesalius Longevity Labs Inc.
0001062993-26-006173 · filed Nov 18, 2026
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Pharmaceuticals filings
Offering
- Industry
- Pharmaceuticals
- Exemptions
- Rule 506(b)
- Reported offering amount
- $13,464,278
- Reported amount sold
- $6,499,999
- Minimum investment
- $0
- Investors
- 9
- Sales commission
- $0
- Finders' fees
- $0
Issuer
- Name
- Vesalius Longevity Labs Inc.
- CIK
- 2131865
- Entity
- Corporation
- Jurisdiction
- BRITISH COLUMBIA, CANADA
- Year incorporated
- —
- Address
- 1500-1055 WEST GEORGIA STREET
VANCOUVER, British Columbia, Canada V6E 4N7 - Phone
- 507-666-6151
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Christopher Cooper · Executive OfficerVancouver, British Columbia, Canada Find on LinkedIn ↗
-
Kevin Serre · DirectorVancouver, British Columbia, Canada Find on LinkedIn ↗
-
Robert McCue · DirectorVancouver, British Columbia, Canada Find on LinkedIn ↗
-
Joel Leonoff · DirectorVancouver, British Columbia, Canada Find on LinkedIn ↗
-
Kevin Mayer · DirectorVancouver, British Columbia, Canada Find on LinkedIn ↗
-
Lee Applbaum · DirectorVancouver, British Columbia, Canada Find on LinkedIn ↗
-
David Adelman · DirectorVancouver, British Columbia, Canada Find on LinkedIn ↗
-
Timmi Stump · Executive OfficerVancouver, British Columbia, Canada Find on LinkedIn ↗
-
Pradeep Albert · Executive OfficerVancouver, British Columbia, Canada Find on LinkedIn ↗
-
James McRoberts · DirectorVancouver, British Columbia, Canada Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗